AstraZeneca to List Directly on NYSE

AstraZeneca is making a major move to woo American investors! The pharmaceutical giant will soon list directly on the New York Stock Exchange, ditching its current Nasdaq ADR setup. This simplifies trading for US investors, potentially boosting the company's global profile and stock value. Is this just a convenience play, or a hint of a bigger shift to the US market on the horizon? Hosted on Acast. See acast.com/privacy for more information.